Janney Montgomery Scott LLC Boosts Position in Enovis Corporation (NYSE:ENOV)

Janney Montgomery Scott LLC lifted its holdings in Enovis Corporation (NYSE:ENOV) by 6.7% during the first quarter, Holdings Channel reports. The fund owned 21,782 shares of the company’s stock after buying an additional 1,366 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Enovis were worth $832,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Envestnet Portfolio Solutions Inc. boosted its holdings in Enovis by 19.5% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 15,433 shares of the company’s stock valued at $677,000 after purchasing an additional 2,518 shares during the last quarter. Mariner LLC grew its holdings in Enovis by 16.8% during the fourth quarter. Mariner LLC now owns 7,925 shares of the company’s stock worth $348,000 after acquiring an additional 1,142 shares during the period. Raymond James Financial Inc. purchased a new position in Enovis during the fourth quarter valued at approximately $16,407,000. Swiss National Bank lifted its holdings in Enovis by 2.5% in the fourth quarter. Swiss National Bank now owns 109,800 shares of the company’s stock valued at $4,818,000 after acquiring an additional 2,700 shares during the period. Finally, Comerica Bank grew its stake in shares of Enovis by 22.9% during the 4th quarter. Comerica Bank now owns 49,560 shares of the company’s stock worth $2,175,000 after purchasing an additional 9,224 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Analyst Ratings Changes

ENOV has been the subject of several analyst reports. Canaccord Genuity Group decreased their target price on shares of Enovis from $75.00 to $70.00 and set a “buy” rating for the company in a research note on Wednesday, May 14th. JMP Securities decreased their price objective on shares of Enovis from $62.00 to $55.00 and set a “market outperform” rating for the company in a research report on Friday, May 9th. Finally, Needham & Company LLC dropped their target price on Enovis from $64.00 to $57.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $58.00.

Enovis Stock Down 1.3%

ENOV opened at $31.36 on Tuesday. The company has a market cap of $1.79 billion, a PE ratio of -2.25 and a beta of 1.72. Enovis Corporation has a twelve month low of $28.83 and a twelve month high of $49.83. The company has a 50-day moving average price of $33.05 and a 200 day moving average price of $38.21. The company has a quick ratio of 1.32, a current ratio of 2.55 and a debt-to-equity ratio of 0.52.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.07. Enovis had a positive return on equity of 5.99% and a negative net margin of 37.65%. The firm had revenue of $558.83 million for the quarter, compared to analyst estimates of $558.80 million. During the same period in the previous year, the company posted $0.50 earnings per share. The business’s revenue was up 8.2% on a year-over-year basis. Sell-side analysts expect that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.